Rasagiline mesylate is an irreversible monoamine oxidase-B (MAO-B) inhibitor frequently prescribed to treat the symptoms of Parkinson’s disease by enhancing dopamine availability in the brain. As part… Read more



















Rasagiline mesylate is an irreversible monoamine oxidase-B (MAO-B) inhibitor frequently prescribed to treat the symptoms of Parkinson’s disease by enhancing dopamine availability in the brain. As part of rigorous pharmaceutical quality control, laboratories require high-quality materials to ensure the efficacy and safety of this medication. This category provides an essential collection of reference standards, including the active ingredient, its relevant metabolites, and pharmacopeial and non-pharmacopeial impurities. These compounds are vital for comprehensive impurity profiling, method validation, and routine analytical testing. By utilizing these characterized substances, researchers and quality control analysts can accurately identify, quantify, and monitor degradation products and stereoisomers throughout the drug development and manufacturing lifecycle. Ensuring the precision of these analytical processes is critical for meeting strict regulatory standards and maintaining consistency in the production of rasagiline mesylate.